Redmile Group LLC trimmed its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 1.4% during the first quarter, Holdings Channel reports. The firm owned 922,678 shares of the company’s stock after selling 13,185 shares during the quarter. IDEAYA Biosciences makes up approximately 1.5% of Redmile Group LLC’s portfolio, making the stock its 24th largest holding. Redmile Group LLC’s holdings in IDEAYA Biosciences were worth $40,487,000 as of its most recent SEC filing.
Several other hedge funds have also bought and sold shares of IDYA. Covestor Ltd increased its position in IDEAYA Biosciences by 9,225.0% during the first quarter. Covestor Ltd now owns 1,119 shares of the company’s stock worth $49,000 after buying an additional 1,107 shares during the last quarter. JTC Employer Solutions Trustee Ltd acquired a new position in shares of IDEAYA Biosciences during the 1st quarter worth approximately $67,000. AJOVista LLC acquired a new position in shares of IDEAYA Biosciences during the 4th quarter worth approximately $99,000. SG Americas Securities LLC bought a new stake in IDEAYA Biosciences in the 1st quarter valued at $101,000. Finally, Bellevue Group AG bought a new position in IDEAYA Biosciences during the first quarter worth $145,000. 98.29% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of analysts have recently issued reports on IDYA shares. JPMorgan Chase & Co. raised their target price on shares of IDEAYA Biosciences from $65.00 to $69.00 and gave the stock an “overweight” rating in a research note on Friday, July 12th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $63.00 target price on shares of IDEAYA Biosciences in a research report on Monday, July 8th. Oppenheimer boosted their price target on IDEAYA Biosciences from $53.00 to $60.00 and gave the company an “outperform” rating in a research note on Monday, July 8th. Royal Bank of Canada upped their price objective on IDEAYA Biosciences from $53.00 to $61.00 and gave the company an “outperform” rating in a report on Thursday, July 11th. Finally, BTIG Research lifted their target price on IDEAYA Biosciences from $55.00 to $62.00 and gave the stock a “buy” rating in a report on Tuesday, July 9th. Fourteen equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $52.92.
IDEAYA Biosciences Stock Performance
Shares of NASDAQ:IDYA traded down $0.14 during midday trading on Monday, hitting $42.25. 611,000 shares of the stock were exchanged, compared to its average volume of 921,372. The business’s 50-day moving average price is $38.38 and its 200 day moving average price is $41.31. IDEAYA Biosciences, Inc. has a 12 month low of $21.22 and a 12 month high of $47.74. The stock has a market capitalization of $3.20 billion, a price-to-earnings ratio of -21.02 and a beta of 0.86.
IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) last posted its earnings results on Tuesday, May 7th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.02). IDEAYA Biosciences had a negative return on equity of 20.09% and a negative net margin of 483.05%. During the same quarter in the prior year, the business earned ($0.49) EPS. The business’s revenue was down 100.0% compared to the same quarter last year. As a group, sell-side analysts expect that IDEAYA Biosciences, Inc. will post -2.22 EPS for the current year.
Insider Buying and Selling
In related news, insider Michael Anthony White sold 28,500 shares of the firm’s stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $36.24, for a total transaction of $1,032,840.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, CEO Yujiro S. Hata sold 34,433 shares of the stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $41.81, for a total transaction of $1,439,643.73. Following the completion of the sale, the chief executive officer now directly owns 677,887 shares in the company, valued at $28,342,455.47. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Michael Anthony White sold 28,500 shares of the business’s stock in a transaction on Wednesday, May 29th. The shares were sold at an average price of $36.24, for a total transaction of $1,032,840.00. The disclosure for this sale can be found here. Insiders have sold a total of 119,644 shares of company stock valued at $4,832,228 over the last 90 days. 3.50% of the stock is owned by insiders.
IDEAYA Biosciences Company Profile
IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.
Read More
- Five stocks we like better than IDEAYA Biosciences
- Stock Market Upgrades: What Are They?
- Survey: Top 175 Fittest Retirement Locations in America
- Learn Technical Analysis Skills to Master the Stock Market
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- What Investors Need to Know About Upcoming IPOs
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Want to see what other hedge funds are holding IDYA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report).
Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.